286 results about "Erythroid cell" patented technology

The invention relates to the technical field of hemodialysis monitoring, and provides a hemodialysis on-line monitoring system and method, and the system comprises a data acquisition module which is used for collecting blood physiological parameters in a dialysis pipeline in real time; the blood component analysis module is connected with a blood loop of the dialysis machine and is used for detecting serum iron, ferritin and ferritin saturation indexes on line; and the data processing module is used for calculating the risk index of anemia, evaluating the iron utilization rate, constructing a model for measuring the iron deficiency erythropoiesis trend according to the collected and analyzed data, and training and optimizing the model. According to the method, individual parameters of patients are fused, personalized calculation is performed for iron metabolism rates and dialysis parameters of different patients, and data such as iron content, blood flow and dialysis fluid volume are acquired online in real time, so that iron concentration and infusion rate are accurately matched with real-time iron metabolism requirements of the patients, and anemia of the patients in the dialysis process is reduced.

The invention belongs to the technical field of biological medicines, and particularly relates to hydrogel with photo-thermal multiple antibacterial and hemostatic functions. The multifunctional hydrogel is prepared from epsilon-polylysine (EPL), gallic acid (GA), tannic acid (TA) and ferric trichloride hexahydrate. The polyphenols are obtained through multiple mechanisms such as reaction between the polyphenols and amino groups, metal chelation, pi-pi interaction and electrostatic attraction (as shown in Figure 1). The metal ion and multiple dynamic cross-linking system hydrogel is constructed, the hydrogel with positive charges enriched on the surface can act with blood platelets with negative charges, red blood cell aggregation, blood platelet adhesion and vasoconstriction effects are promoted, and the blood coagulation efficiency is improved. The hydrogel shows excellent antibacterial performance and photo-thermal performance, can prevent infection in the inflammation stage of wound healing, can effectively accelerate wound healing, and has good biological safety.

The present embodiments are directed to methods of using glycine transporter inhibitors, such as GlyT1 inhibitors, or pharmaceutically acceptable salts, solvates or prodrugs thereof, or pharmaceutical compositions thereof, for preventing or treating erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLPP), and / or congenital erythropoietic porphyria (CEP), and related syndromes thereof.

The invention relates to the technical field of medical care informatics and precision medical treatment, and discloses a hemodialysis patient precision medication system based on multiple omics and big data, and the system comprises a multi-source data collection module which collects the multi-source heterogeneous data of a patient and carries out the standardization and integration processing; the drug metabolism analysis module is used for analyzing drug metabolism paths and individual differences through multi-omics data, constructing a drug metabolism polymorphic model and outputting gene metabolism capability grades and biomarker risk tags; the initial medication decision-making module is used for constructing an initial medication decision-making model based on a federal optimization framework of a momentum enhancement and robust aggregation mechanism, and outputting a personalized initial medication scheme for erythropoietin and a vein iron agent; and the drug dosage adjustment module is used for dynamically optimizing the time node and dosage adjustment opportunity of drug administration through an asynchronous federal reinforcement learning framework in combination with a prospective parameter correction strategy. According to the invention, the intelligent medication system with strong robustness and fine decision is constructed.

Provided herein is a recombinant protein comprising a transmembrane domain derived from a transmembrane domain of a wild type erythropoietin receptor (EPOR). Nucleic acid molecules encoding such recombinant proteins, recombinant constructs, vectors and cells containing the nucleic acid molecules, methods of producing such cells and therapeutic uses thereof are also provided.

The invention provides application of qi-blood foundation strengthening oral liquid in preparation of a medicine for building body and resisting aging, and belongs to the technical field of medicine preparations. According to the invention, the mass ratio relationship among the components and the preparation method thereof are researched, and especially in the preparation process, the traditional Chinese medicine components are extracted by adopting the modes of high-pressure steam heating, vacuum concentration and the like under different pressures in batches and stages, so that the obtained oral liquid for consolidating qi and blood not only has the effective component content, but also has the health-care effect. The oral liquid for consolidating qi and blood has the effects of improving the activity of superoxide dismutase of red blood cells and reducing the content of lipofuscin in tissues, can improve the exercise tolerance of rats, and has the effects of resisting aging and building the body.

The present disclosure provides methods of treating anemia in a patient in need thereof, comprising administering to the patient in need thereof an effective amount of salmeterol or a pharmaceutically acceptable salt thereof. Salmeterol or a pharmaceutically acceptable salt thereof may be administered conjointly with an erythropoiesis-stimulating agent, optionally wherein the anemia is refractory to the erythropoiesis-stimulating agent. Also provided are methods of promoting differentiation of an erythroid progenitor cell toward a mature red blood cell in a patient in need thereof, comprising administering an effective amount of salmeterol or a pharmaceutically acceptable salt thereof. The present disclosure further provides methods comprising administering salbutamol or a pharmaceutically acceptable salt thereof. Salmeterol, salbutamol, or a pharmaceutically acceptable salt thereof may be administered conjointly with other FDA-approved drugs such as luspatercept, lenalidomide, daprodustat, vadadustat, an erythropoiesis-stimulating agent (ESA), and / or a hypomethylating agent.

The present disclosure provides, among other things, methods, compositions, and uses for treating diseases or disorders characterized by elevated red blood cells using β2 adrenergic receptor antagonists such as β2-specific adrenergic receptor antagonists (e.g., ICI-118551, butaxamine, or pharmaceutically acceptable salts thereof) or β1 / β2-specific adrenergic receptor antagonists (e.g., propranolol or a pharmaceutically acceptable salt thereof). Also provided are methods, compositions, and uses for decreasing erythroid differentiation using the same. Provided methods of treatment comprise administering an effective amount of a β2-specific adrenergic receptor antagonist or a β1 / β2-specific adrenergic receptor antagonist to a patient in need thereof. Also provided are methods, compositions, and uses for ICI-118551 in treating splenomegaly, splenic erythroid hyperplasia, and / or splenic architecture effacement.

The invention belongs to the technical field of biological medicine, and particularly relates to a chitosan modified gold nanocluster, a preparation method and application in red blood cell immobilization. According to the synthesis method of the CS-GSH-AuNCs cluster, a two-step low-temperature modification method is utilized, GSH-AuNCs core nanoparticles with a definite structure are synthesized firstly, then chitosan is modified through electrostatic interaction, the reaction condition is low temperature and nitrogen protection, the reaction condition is mild, the product repeatability is high, and the original structure of GSH-AuNCs is more complete. Experiments show that the CS-GSH-AuNCs cluster synthesized by the method has good acid and alkali tolerance and temperature tolerance, the effect of immobilizing red blood cells is good, and the biological safety is high.

The present embodiments are directed to methods of using glycine transporter inhibitors, such as GlyT1 inhibitors, or pharmaceutically acceptable salts, solvates or prodrugs thereof, or pharmaceutical compositions thereof, for preventing or treating erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLPP), and / or congenital erythropoietic porphyria (CEP), and related syndromes thereof.

A method for promoting erythrocyte differentiation is provided. A method for increasing RNA polymerase II arrest mediated by the MED26 polypeptide is also provided. Furthermore, a method for delivering reagents to cells is also provided.

The invention relates to an erythrocyte specific antibody screening test kit expressing a single antigen from a target erythrocyte (RBC) antigen (RhD and RhCE as 2 different antigens derived from RBC and 45 or more antigens in total including some variants of these two antigens) and a preparation method of this test kit. Said antigens are transgenically produced and provide the clearest results compared to traditional methods of antibody screening. Field-targeted mutation process is applied during the preparation of the erythrocyte-specific antibody screening test kit subject to the invention.

The present disclosure relates to methods of treating myelodysplastic syndrome. The present disclosure provides methods of treating myelodysplastic syndrome (MDS) in a subject not treated with an agent selected from a hypomethylating agent (HMA) and lenalidomide, or both. The methods comprise administering to the subject an effective amount of a telomerase inhibitor, such as, for example, imestat or imestat sodium. In some cases, a subject being treated is classified as a low or moderate-1IPSS risk MDS subject and / or has an erythropoiesis stimulating agent (ESA) recurrent / refractory MDS.

Reading device (10) for measuring the erythrocyte sedimentation rate starting from a blood sample consisting of a drop of a few microliters, which exploits capillarity to move the sample.

The present disclosure provides, in various aspects and embodiments, methods for generating hematopoietic lineages for cell therapy, including erythroid progenitor cells, progenitor cell erythroblasts, granulocyte-macrophage progenitor cells (GMP), and megakaryocyte erythroid progenitor cells (MEPs) and erythroid cells. In various embodiments, the invention provides efficient in vitro methods for developing such hematopoietic lineages, including but not limited to progenitor erythroblasts and erythroblasts lineages, from human induced pluripotent stem cells (iPSCs). The cells produced in various embodiments according to the present disclosure are functional and / or more closely similar to corresponding lineages isolated from peripheral blood or bone marrow. The invention also provides isolated cells and cell compositions produced by the methods disclosed herein, as well as methods for cell therapy.

The present invention relates to a method for differentiating canine hematopoietic stem cells into erythrocytes through in vitro culture, and a method for producing canine erythrocytes using same. According to the method, erythrocytes can be effectively produced from canine hematopoietic stem cells by using cytokines at specific concentrations.

The invention belongs to the technical field of biology, and particularly relates to ANK1 gene nonsense mutation and application. The invention firstly provides an ANK1 gene non-sense mutation c.2230 Cgt and an ANK1 gene non-sense mutation c.2230 Cgt. The invention relates to the field of genetic engineering, and in particular relates to nonsense mutation T (p.Q744X), the nonsense mutation significantly reduces the expression of ankyrin, and further causes phenotypic changes such as abnormal cell morphology and increased osmotic fragility after K562 erythroid differentiation, which indicates that the K562 is related to the pathological process of hereditary polycythemia spheroides (HS), and indicates that the mutation has pathogenicity; secondly, a treatment evaluation system taking drug-induced translation readthrough and adenine base editing as a core is constructed around the mutation, a new strategy and a technical platform are provided for precise molecular treatment of the ANK1 nonsense mutant HS, and important clinical transformation prospects and application values are achieved.

This invention belongs to the field of animal model construction technology, specifically relating to a mouse immunosuppressive model that maintains a long-term immunosuppressive state, its construction method, and its application. This invention establishes a stable immunosuppressive state model with reduced neutrophil count and no significant decrease in erythrocyte count by administering different doses of immunosuppressants (10-50 mg / kg body weight) to Balb / c mice via a combination of "reduced total dose + multiple gavage administration + satellite monitoring." The method for constructing this mouse immunosuppressive model reduces drug usage, controls neutrophil count rebound, establishes a stable model of reduced neutrophil count, and avoids deep bone marrow suppression (i.e., does not cause an uncontrollable decrease in erythrocyte or platelet count), which is beneficial for long-term experimental conduct and drug evaluation.

The invention discloses an application of a natural product WithangatinA in preparation of erythroleukemia induced differentiation treatment drugs, the natural product WithangatinA promotes HEL and K562 cells to be transformed from malignant proliferative cells to normal megakaryocytes by inducing the cell particle size to become larger and significantly increasing multinuclear megakaryocytes and promoting expression of surface labeled molecules differentiated from megakaryocytes at the same time, and the erythroleukemia induced differentiation treatment drugs are obtained. The effect of resisting erythroleukemia is achieved. After the natural product Withangulin A is adopted for treatment, the size and the weight of the spleen of a leukemia mouse can be remarkably reduced, the hematocrit and the platelet number of the mouse are remarkably increased, in addition, treatment of the natural product Withangulin A has no obvious influence on the weight of the mouse, and the safety is high. In-vivo research shows that the medicine can induce megakaryocyte differentiation of erythroleukemia in a mouse body, the effect of resisting erythroleukemia is achieved, and a research basis is provided for development of differentiation treatment medicines of erythroleukemia.

To provide a novel erythropoietin production promoter.SOLUTION: An erythropoietin production promoter contains isorhamnetin and / or an isorhamnetin glycoside as an active ingredient.SELECTED DRAWING: Figure 1

Compositions comprising Lumbricus terrestris erythrocruorin (LtEc) as an oxygen carrier for use in transfusion and organ perfusion are provided. In particular, methods of using acellular compositions comprising LtEc as a universal blood substitute for transfusion of patients are provided. The methods also include ex vivo perfusion of an organ or tissue with an oxygenated acellular perfusate comprising LtEc as an oxygen carrier. Additionally, methods are provided for using compositions comprising LtEc in treatment of acute ischemia and hyperbaric oxygen therapy.

A system for measuring erythrocyte sedimentation rates in blood samples is described having a support for a tube containing a blood sample, an agitating element to agitate the tube, a detection unit to perform an optical measurement on the blood sample, moving means to cause movement between the detection unit and the tube during the optical measurement, and a processing unit to process signals from the detection unit. The processing unit creates a reading curve corresponding to the absorption of radiation emitted by the detection unit as a function of the relative movement between the detection unit and the tube and defines an ideal trapezoidal curve to approximate the reading curve to generate an optimized ideal curve, and generate a value indicative of the erythrocyte sedimentation rate of the blood sample in the tube. The system also includes output means to output measurement results based on the generated values.

Therapeutic methods and pharmaceutical compositions for treating a myeloproliferative neoplasm (MPN), including polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis, are described. In certain embodiments, the invention includes therapeutic methods of treating a MPN using a combination of a compound of Formula (I) or Formula (II) with a therapeutic agent selected from the group consisting of a JAK inhibitor, an IDH inhibitor, a PD-1 inhibitor, a PD-L1 inhibitor, a PD-L2 inhibitor, an interferon, a PI3K inhibitor, an AKT inhibitor, an mTOR inhibitor, a nucleoside analog, and combinations thereof.

The present invention relates to the use of ligustrazine nitrone derivatives and pharmaceutical composition thereof for the treatment and prevention of diseases of diabetic complications, which include renal anemia. The ligustrazine nitrone derivatives have the structure of the general formula (I).Experimental results indicated that the ligustrazine nitrone derivatives can significantly increase the levels of serum iron and erythropoietin in STZ induced SD rats and spontaneously hypertensive rats, and can be used for treating and preventing renal anemia caused by decrease in renal EPO production and / or concomitant iron deficiency. Therefore, the ligustrazine nitrone derivatives can be made into various dosage forms with a drug carrier. The derivatives can be prepared into various dose forms together with drug carriers.

The invention concerns a method for determining, by flow cytometry, the hemoglobin content of each erythroid cell of a set of erythroid cells. This method applies in particular to determining the hemoglobin content of each red blood cell of a set of red blood cells. The invention also concerns a method for determining the amount of red blood cells transfused into a patient and for monitoring the therapeutic efficacy of a treatment for sickle cell disease or β-thalassemia.

The invention relates to the technical field of biomedicine, in particular to a serum protein marker for ossification of ligamentum flavum and application of the serum protein marker. The serum protein marker comprises erythrocyte glucose phosphate isomerase and / or dystrophin associated glycoprotein 1. According to the method, a data-independent quantitative proteomics strategy is utilized to compare a normal healthy control (a patient who does not suffer from ligamentum flavum ossification and needs spinal surgery to take ligamentum flavum tissues) with a ligamentum flavum ossification patient; it is found that ligamentum flavum ossification-related proteins, namely erythrocyte glucose phosphate isomerase (GPI) and dystrophy protein-related glycoprotein 1 (DAG1), with the obviously-changed expression quantity in tissue are beneficial to diagnosis of patients with ligamentum flavum ossification and provide effective targets for development of treatment methods of the ligamentum flavum ossification.

Provided is a cell culture method including introducing a factor into cells in a cell culture vessel, and culturing the cells into which the factor has been introduced in the same cell culture vessel. Also provided is a mononuclear cell collection method including treating blood to prepare a treated blood from which erythrocytes have been at least partially removed, diluting the treated blood, causing sedimentation of mononuclear cells contained in the diluted treated blood, removing the supernatant from the diluted treated blood, and collecting the mononuclear cells.

The present disclosure relates to a SURF4 gene-knockout erythroid progenitor cell and a method of differentiating the same into an erythrocyte, wherein it has been determined that SURF4 gene-knockout cells, in which a SURF4 gene is knocked out in erythroid progenitor cells, express erythroid differentiation markers at a higher rate and undergo erythroid differentiation more rapidly under erythroid differentiation conditions according to the present disclosure, such that the present disclosure provides a method that enables rapid differentiation of erythrocytes using SURF4 gene-knockout erythroid progenitor cells.

The invention relates to chimeric Plasmodium antigenic polypeptides derived from pre-erythrocytic (PE) antigens and associated in a fusion polypeptide. In particular, the invention relates to antigenic fusion polypeptides of malaria parasites wherein said antigenic polypeptides exhibit a protective effect, especially that of eliciting a protective immune response in a host against challenge by Plasmodium sporozoites or a sterile response. Such identified antigenic fusion polypeptides may thus constitute active ingredients suitable for the design of a vaccine candidate, in particular a vaccine suitable for a human host.

This disclosure provides methods of treating a myelodysplastic syndrome (MDS) in a subject that is naive to treatment with an agent selected from a hypomethylating agent (HMA) and lenalidomide, or both. The method includes administering to the subject an effective amount of a telomerase inhibitor, such as e.g. imetelstat or imetelstat sodium. In some cases, the subject treated is classified as low or intermediate-1 IPSS risk MDS and / or have MDS relapsed / refractory to Erythropoiesis-Stimulating Agent (ESA).